Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Mevalonate kinase deficiency Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 Mevalonate kinase deficiency indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Deficiency of interleukin-1 receptor antagonist Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 Deficiency of interleukin-1 receptor antagonist indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
Cryopyrin-associated periodic syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 Cryopyrin-associated periodic syndrome indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
TAFRO syndrome Indication Strategy Report 2026: IL-6, Trials and Deals
30 July 2026
2026 TAFRO syndrome indication strategy covering epidemiology, IL-6 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Juvenile xanthogranuloma Indication Strategy Report 2026: MAPK, Trials and Deals
30 July 2026
2026 Juvenile xanthogranuloma indication strategy covering epidemiology, MAPK biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Multicentric reticulohistiocytosis Indication Strategy Report 2026: TNF, Trials and Deals
30 July 2026
2026 Multicentric reticulohistiocytosis indication strategy covering epidemiology, TNF biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Schnitzler syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 Schnitzler syndrome indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Transient abnormal myelopoiesis Indication Strategy Report 2026: GATA1, Trials and Deals
30 July 2026
2026 Transient abnormal myelopoiesis indication strategy covering epidemiology, GATA1 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Myeloid/lymphoid neoplasm with FGFR1 rearrangement Indication Strategy Report 2026: FGFR1, Trials and Deals
30 July 2026
2026 Myeloid/lymphoid neoplasm with FGFR1 rearrangement indication strategy covering epidemiology, FGFR1 biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
Acute erythroid leukemia Indication Strategy Report 2026: BCL2, Trials and Deals
30 July 2026
2026 Acute erythroid leukemia indication strategy covering epidemiology, BCL2 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Acute megakaryoblastic leukemia Indication Strategy Report 2026: MPL, Trials and Deals
30 July 2026
2026 Acute megakaryoblastic leukemia indication strategy covering epidemiology, MPL biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Breast implant-associated anaplastic large cell lymphoma Indication Strategy Report 2026: CD30, Trials and Deals
30 July 2026
2026 Breast implant-associated anaplastic large cell lymphoma indication strategy covering epidemiology, CD30 biology, active trials, transactions, unmet need,…